Medical Policy Unit Part A and B Updates for October 1, 2008

Acid Phosphatase
L25879 (R2) (effective 10/01/2008): LCD revised effective October 1, 2008 for annual ICD-9-CM update: added codes 205.02, 205.12, 205.22, 205.32, 205.82, and 205.92 as payable for CPT code 84060; code descriptors revised for 205.00, 205.10, 205.20, 205.30, 205.80, and 205.90.

Apheresis
L26865 (R2) (effective 10/01/2008): Source of revision - Internal (annual ICD-9-CM code updates for 2009). The “ICD-9-CM Codes That Support Medical Necessity” section of the policy is revised with new descriptor for the following codes: 203.00, 203.10, 204.00, 204.10, 204.20, 204.80, 204.90, 205.00-205.90, 206.00-206.90, 207.00-207.80 and 208.00-208.90. In addition, per the FDA approval the last sentence has been deleted from the last paragraph in the “Abstract” regarding the registry tracking process. Finally, several minor changes are made to reflect the current CMS and National Government Services current policy formats. No comment and notice periods required and none given.

Botulinum Toxins Type A and Type B
L26841 (R2) (effective 10/01/2008): Source of revision - Internal (annual ICD-9-CM code updates for 2009). For CPT codes 64612, 64613 in the “ICD-9 Codes that Support Medical Necessity” section that specifies “coverage for carefully-selected patients with previously demonstrated response to Botulinum toxin therapy for intractable headache unresponsive and refractory to standard and usual conventional therapy” were updated as follows:

ICD-9-CM code 307.81 was deleted from the "ICD-9 Codes that Support Medical Necessity" section of the policy and was replaced with ICD-9-CM code 339.12.

The descriptions for ICD-9-CM codes 346.01, 346.11 and 346.91 were updated.

Breast Imaging: Mammography/Breast Echography (Sonography)/Breast MRI/Ductography
L26890 (R2) (effective 10/01/2008): Source of revision - Internal (annual ICD-9-CM code update for 2009). ICD-9-CM code 611.8 was deleted from the “ICD-9-CM Codes That Support Medical Necessity” section of the LCD. ICD-9-CM code 611.89 was added as the replacement code. ICD-9-CM code 612.0 and 612.1 were added. No comment and notice periods required and none given.

Cardiovascular Nuclear Medicine
L26859 (R2) (effective 10/01/2008): LCD revised effective October 1, 2008 for annual ICD-9-CM update: added ICD-9-CM code 414.3 as payable for CPT codes 78460, 78461, 78464, 78465, 78472, 78473, 78478, 78480, 78481, 78483, 93015, 93016, 93017 and 93018.

Colonoscopy/Sigmoidoscopy/Proctosigmoidoscopy
L26404 (R2) (effective 10/01/2008): Source of revision – Internal (Annual ICD-9-CM code update for 2009). New ICD-9-CM codes added are: 209.10, 209.11, 209.12, 209.13, 209.14, 209.15, 209.16, 209.17, 209.20, 209.27, 209.29, 209.30, 209.50, 209.51, 209.52, 209.53, 209.54, 209.55, 209.56, 209.57, 209.60, 558.41, 558.42 and 569.44.

No comment period required and none given.

Computed Tomographic (CT) Colonography
L25233 (R2) (effective 10/01/2008): Source of revision internal. (Annual ICD-9-CM code update for 2009). New ICD-9-CM codes added are: 209.10, 209.11, 209.12, 209.13, 209.14, 209.15, 209.16, 209.17, 209.50, 209.51, 209.52, 209.53, 209.54, 209.55, 209.56, 209.57, 558.42, 777.50, 777.51, 777.52 and 777.53.

No comment or notice period required or given.

Endoscopy by Capsule
L25468 (R2) (effective 10/01/2008): Source of revision - Internal (annual ICD-9-CM code update for 2009). ICD-9-CM codes 209.00, 209.01, 209.02, 209.03, 209.40, 209.41, 209.42, 209.43, 558.41 and 558.42 were added to the ICD-9-CM code listing for CPT code 91110 in the “ICD-9-CM Codes That Support Medical Necessity” section of the LCD. Corrected explanatory note in the “ICD-9-CM Codes That Support Medical Necessity” section to read: ICD-9-CM code V45.89 for purposes of this LCD indicates that medically necessary flexible upper and lower flexible endoscopy were carried out before endoscopy by capsule was done. Therefore, ICD-9-CM code V45.89 must be reported on all claims for endoscopy by capsule of the small bowel except for some patients suspected of having Crohn’s disease in order for coverage to occur. In addition to reporting ICD-9-CM code V45.89, one (or more) of the ICD-9-CM codes above must be reported in order to support medical necessity. No comment and notice periods required and none given.

Erythropoietin Stimulating Agents (ESA)
L25211 (R7) (effective 10/01/2008): Change Request: 6107 Medicare Contractor Annual Update of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)

Addition of ICD-9-CM codes for patients with anemia related to chemotherapy 203.02, 203.12, 203.82, 204.02, 204.12, 204.22, 204.82 and 204.92.

Descriptor change for ICD-9-CM 203.00, 203.10, 203.80, 204.00, 204.10, 204.20, 204.80, and 204.90.

Erythrocyte Sedimentation Rate (ESR)
L25639 (R3) (effective 10/01/2008): Source of revision - Internal (annual ICD-9-CM code updates for 2009). "The ICD-9-CM Codes That Support Medical Necessity" section of the policy is expanded with the addition of ICD-9-CM code 482.42 and the revision of ICD-9-CM code 482.41.

No comment and notice periods required and none given.

Esophagogastroduodenoscopy (EGD)
L26394 (R2) (effective 10/01/2008): Source of revision - Internal (annual ICD-9-CM code update for 2009). ICD-9-CM codes 209.00, 209.01, 209.02, 209.23 209.25, 209.26, 209.30, 209.40, 209.41, 209.42, 209.63, 209.65, 209.66, 530.13, 535.70, 535.71, 558.41 were added to the ICD-9-CM code listing for CPT codes 43200-43228, 43234-43236, 43239-43241, 43243-43251, 43255, 43256, 43258, 74235, and 74360 and ICD-9-CM codes 209.00, 209.01, 209.10, 209.12, 209.13, 209.14, 209.15, 209.16, 209.20, 209.21, 209.22, 209.23, 209.25, 209.26, 209.27, 209.29, 209.30, 209.40, 209.41, 209.42, 209.63, 209.65, 209.66 and 209.69 for CPT codes 43231, 43232, 43237, 43238, 43242 and 43259 in the “ICD-9-CM Codes That Support Medical Necessity” section of the LCD.

Nerve Conduction Studies (NCS)/Electromyography (EMG)
L26869 (R2) (effective 10/01/2008): LCD revised effective October 1, 2008 for annual ICD-9-CM update: added codes 249.60, 249.61, 788.91, and 788.99. Code 337.0 is deleted and replaced by codes 337.00 and 337.09.

Neuromuscular Junction Testing
L25563 (R2) (effective 10/01/2008): Source of revision - Internal (annual ICD-9-CM code updates for 2009). For CPT code 95937 the “ICD-9 Codes that DO NOT Support Medical Necessity” (coding list #2) section was updated as follows:

ICD-9-CM code 729.9 was deleted and replaced with ICD-9-CM codes 729.90 and 729.99.

No notice period required and none given.

Ophthalmic Angiography (Fluorescein and Indocyanine Green)
L25347 (R2) (effective 10/01/2008): LCD revised effective October 1, 2008 for annual ICD-9-CM update: added codes 249.50 and 249.51 as payable for CPT code 92235.

Ophthalmology: Posterior Segment Imaging (Extended Ophthalmoscopy and Fundus Photography)
L25466 (R2) (effective 10/01/2008): LCD revised effective October 1, 2008 for annual ICD-9-CM update: added codes 249.50, 249.51, 362.20, 362.22-362.27, and 362.82 as payable for CPT codes 92225, 92226 and 92250; added codes 249.00, 249.01, 249.10, 249.11, 249.20, 249.21, 249.30, 249.31, 249.40, 249.41, 249.60, 249.61, 249.70, 249.71, 249.80, 249.81, 249.90, and 249.91 as payable for CPT codes 92225 and 92226.

Post-Void Residual Urine and/or Bladder Capacity by Ultrasound
L26882 (R2) (effective 10/01/2008): LCD revised effective October 1, 2008 for annual ICD-9-CM update: code 788.9 replaced by codes 788.91 and 788.99.

Radiologic Examination of the Chest
L26901 (R2) (effective 10/01/2008): Source of revision - Internal (annual ICD-9-CM code updates for 2009). The "ICD-9-CM Codes That Support Medical Necessity" section of the policy is modified as follows: The description for ICD-9-CM codes 203.00, 203.10, 203.80 and 482.41 have been modified. ICD-9-CM code 482.42 has been added. ICD-9-CM code 511.8 has been deleted and replaced with 511.81 and 511.89. ICD-9-CM code 780.6 has been deleted and is being replaced with 780.60, 780.61, 780.62, 780.64 and 780.65. ICD-9-CM code 997.3 has been deleted and is being replaced with 997.31 and 997.39.

No notice period required and none given.

Routine Foot Care and Debridement of Nails
L26426 (R2) (effective 10/01/2008): LCD revised effective October 1, 2008 for annual ICD-9-CM update: added codes 249.40, 249.41, 249.50, 249.51, 249.60, 249.61, 249.70, and 249.71 as payable for CPT codes 11055, 11056, 11057, 11719, 11720, and G0127 if the active care requirement is met.

Surgical Decompression for Peripheral Polyneuropathy
L25271 (R2) (effective 10/01/2008): Source of revision - Internal (annual ICD-9-CM code updates for 2009). For CPT codes 01470, 28035, 64702, 64704, 64708, 64712, 64714, 64722, 64726, 64727 the “ICD-9 Codes that Support Medical Necessity” section was updated as follows:

ICD-9-CM codes 249.60 and 249.61 were added.

No notice period required and none given.

Vertebroplasty and Kyphoplasty (Percutaneous)
L26439 (R2) (effective 10/01/2008): Source of revision - Internal (annual ICD-9-CM code updates for 2009). For CPT codes 22520, 22521, 22521, 22522, 22523, 22524, 22525, 72291, 72292, 76380 (secondary diagnosis list) the “ICD-9 Codes that Support Medical Necessity” section was updated as follows:

ICD-9-CM code 203.02 was added.

The description for ICD-9-CM code 203.00 was updated.

Visual Fields Testing
L26367 (R2 )(effective 10/01/2008): Source of revision - Internal (annual ICD-9-CM code updates for 2009). The “ICD-9-CM Codes That Support Medical Necessity” section of the policy is revised with new descriptor for the following codes: 346.00, 346.01, 346.20, 346.21, 346.80, 346.81, 346.90 and 346.91. Finally, several minor changes are made to reflect the current CMS and National Government Services current policy formats.

No comment and notice periods required and none given.

Cardiac Catheterization and Coronary Angiography– Supplemental Instructions Article (SIA) A46193 (Article published October 2008): The Hospital Outpatient Claim section has been revised:

Cardiac catheterizations for which an overnight stay is anticipated, for routine recovery, should not be billed as inpatient services. Furthermore, the routine recovery period should not be billed as observation hours in addition to the catheterization unless the patient has sustained untoward complications necessitating the continued monitoring. An inpatient or observation stay following a routine outpatient cardiac catheterization would be considered not medically necessary and denied.
Anterior segment scanning computerized ophthalmic diagnostic imaging (0187T) – Medical Policy Article
A48043 Correction (published 09/25/2008) (effective 09/01/2008): In the “Coding Guidelines” section of the article, “ambulatory service center” has been corrected to “ambulatory surgical center.”

Apligraf –Related to LCD L26003
A46092 (Article published October 2008): Change Request: 6107 Medicare Contractor Annual Update of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)

Addition of ICD-9-CM codes 249.00, 249.01, 249.10, 249.11, 249.20, 249.21, 249.30, 249.31, 249.40, 249.41, 249.50, 249.51, 249.60, 249.61, 249.70, 249.71, 249.80, 249.81, 249.90 and 249.91.

Azacitidine (e.g., Vidaza ™) - Related to LCD L25820
A46099 (Article published October 2008): Source of revision – Internal (annual ICD-9-CM code updates for 2009). The “ICD-9-CM Codes That Support Medical Necessity” section of the article is modified as follows: the description for ICD-9-CM codes 205.00, 205.10 and 205.20 has been modified. ICD-9-CM codes 205.02, 205.12 and 205.22 have been added.

Bortezomib (e.g., Velcade®) – Related to LCD L25820
A47582 (Article published October 2008): Source of revision – Internal (annual ICD-9-CM code updates for 2009). The “ICD-9-CM Codes That Support Medical Necessity” section of the article is modified as follows: the description for ICD-9-CM code 203.00 has been modified. ICD-9-CM code 203.02 has been added.

Carboplatin (Paraplatin®, Paraplatin-AQ®) – Related to LCD L25820
A47583 (Article published October 2008): Source of revision – Internal (annual ICD-9-CM code updates for 2009). The “ICD-9-CM Codes That Support Medical Necessity” section of the article is modified as follows: the description for ICD-9-CM codes 204.00, 204.10, 204.20, 204.80, 204.90, 205.00, 205.10, 205.20, 205.30, 205.80, 205.90, 206.00, 206.10, 206.20, 206.80, 206.90, 207.00, 207.10, 207.20, 207.80, 208.00, 208.10, 208.20, 208.80 and 208.90 has been modified. ICD-9-CM codes 204.02, 204.12, 204.22, 204.82, 204.92, 205.02, 205.12, 205.22, 205.32, 205.82, 205.92, 206.02, 206.12, 206.22, 206.82, 206.92, 207.02, 207.12, 207.22, 207.82, 208.02, 208.12, 208.22, 208.82 and 208.92 have been added. The first sentence in “Indications” has been revised to remove “FDA.”

Decitabine (e.g., Dacogen™) – Related to LCD L25820
A46086 (Article published October 2008): Source of revision – Internal (annual ICD-9-CM code updates for 2009). The “ICD-9-CM Codes That Support Medical Necessity” section of the article is modified as follows: the description for ICD-9-CM codes 205.00 and 205.10 has been modified. ICD-9-CM codes 205.02 and 205.12 have been added.

Denileukin Difitox (e.g., Ontak ®) – Related to LCD L25820
A46097 (Article published October 2008): Source of revision – Internal (annual ICD-9-CM code updates for 2009). The “ICD-9-CM Codes That Support Medical Necessity” section of the article is modified as follows: the description for ICD-9-CM code 204.10 has been modified. ICD-9-CM code 204.12 has been added.

Dermagraft ® – Related to LCD L26003
A46090 (Article published October 2008): Change Request: 6107 Medicare Contractor Annual Update of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)

Addition of ICD-9-CM codes 249.00, 249.01, 249.10, 249.11, 249.20, 249.21, 249.30, 249.31, 249.40, 249.41, 249.50, 249.51, 249.60, 249.61, 249.70, 249.71, 249.80, 249.81, 249.90 and 249.91.

Doxorubicin HCl – Related to LCD L25820
A47584 (Article published October 2008): Source of revision – Internal (annual ICD-9-CM code updates for 2009). The “ICD-9-CM Codes That Support Medical Necessity” section of the article is modified as follows: the description for ICD-9-CM codes 203.00, 204.00, 204.10, 205.00, 205.10, 205.20, 205.30, 205.80, 205.90, 206.00 and 207.00 has been modified. ICD-9-CM codes 203.02, 204.02, 204.12, 205.02, 205.12, 205.22, 205.32, 205.82, 205.92, 206.02, 207.02, 209.00-209.03, 209.10-209.17, 209.20-209.27, 209.29, 209.40-209.43, 209.50-209.57, 209.60-209.67 and 209.69 have been added.

Doxorubicin, Liposomal (Doxil) – Related to LCD L25820
A47585 (Article published October 2008): Source of revision – Internal (annual ICD-9-CM code updates for 2009). The “ICD-9-CM Codes That Support Medical Necessity” section of the article is modified as follows: the description for ICD-9-CM code 203.00 has been modified. ICD-9-CM code 203.02 has been added.

Etoposide (Etopophos®, Toposar®, Vepesid®, VP-16) – Related to LCD L25820
A47586 (Article published October 2008): Source of revision – Internal (annual ICD-9-CM code updates for 2009). The “ICD-9-CM Codes That Support Medical Necessity” section of the article is modified as follows: the description for ICD-9-CM codes 203.00, 204.00, 205.00, 205.10, 206.00 and 207.00 has been modified. ICD-9-CM codes 203.02, 204.02, 205.02, 205.12, 206.02, 207.02 and 238.77 have been added. The name of the drug has been corrected in the “Coding Guidelines” section. The first sentence in “Indications” has been revised to remove “FDA.”

Ifosfamide (Ifex) - Related to LCD L25820
A47579 (Article published October 2008): Source of revision – Internal (annual ICD-9-CM code updates for 2009). The “ICD-9-CM Codes That Support Medical Necessity” section of the article is modified as follows: the description for ICD-9-CM code 204.00 has been modified. ICD-9-CM code 204.02 has been added.

Integra ® Dermal Regeneration Template, Integra ® Bilayer Matrix Wound Dressing – Related to LCD L26003
A46085 (Article published October 2008) Correction: Removal of CPT codes 15002, 15003, 15004, 15005, 15100, 15101, 15110, 15111, 15115, 15116, 15120 and 15121 from the CPT/HCPC code list and coding guidelines. These CPT/HCPCs codes do not apply to this article.

Intravenous Immune Globulin (IVIG) - Related to LCD L25820
A47381 (Article published October 2008): Source of revision – Internal (annual ICD-9-CM code updates for 2009). The “ICD-9-CM Codes That Support Medical Necessity” section of the article is modified as follows: the description for ICD-9-CM codes 203.00, 203.10, 203.80 and 204.10 has been modified. ICD-9-CM codes 203.02, 203.12, 203.82 and 204.12 have been added.

Irinotecan Hydrochloride (e.g., Camptosar®) - Related to LCD L25820
A46757 (Article published October 2008): Source of revision – Internal (annual ICD-9-CM code updates for 2009). The “ICD-9-CM Codes That Support Medical Necessity” section of the article is modified as follows: the description for ICD-9-CM codes 204.00 and 205.00 has been modified.

Mitomycin (Mutamycin®, Mitomycin-C) – Related to LCD L25820 (A47581)
Article published October 2008: Source of revision – Internal (annual ICD-9-CM code updates for 2009). The “ICD-9-CM Codes That Support Medical Necessity” section of the article is modified as follows: the description for ICD-9-CM codes 205.10 has been modified. ICD-9-CM code 205.12 has been added.

OASIS ® Wound Matrix and Oasis® Burn Matrix – Related to LCD L26003
A46082 (Article published October 2008): Change Request: 6107 Medicare Contractor Annual Update of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)

Addition of ICD-9-CM codes 707.20, 707.21, 707.22, 707.23, 707.24, 707.25, 998.30 and 998.33.

Oprelvekin (e.g., Neumega®) – Related to LCD L25820
A46098 (Article published October 2008): Source of revision – Internal (annual ICD-9-CM code updates for 2009). The “ICD-9-CM Codes That Support Medical Necessity” section of the article is modified as follows: ICD-9-CM codes 209.00-209.03, 209.10-209.17, 209.20-209.27 and 209.29 have been added to the “Secondary ICD-9-CM codes” listing.

Paclitaxel (e.g., Taxol®/Abraxane ™) - Related to LCD L25820
A46758 (Article published October 2008): Source of revision – Internal (annual ICD-9-CM code updates for 2009). The “ICD-9-CM Codes That Support Medical Necessity” section of the article is modified as follows for paclitaxel only: the description for ICD-9-CM code 203.00 has been modified. ICD-9-CM code 203.02 has been added.

Pamidronate Disodium for Injection (e.g., Aredia®) - Related to LCD L25820
A46738 (Article published October 2008): Source of revision – Internal (annual ICD-9-CM code updates for 2009). The “ICD-9-CM Codes That Support Medical Necessity” section of the article is modified as follows:

In the ICD-9-CM code table for “Osteolytic lesions of multiple myeloma”, the description for ICD-9-CM code 203.00 has been modified and ICD-9-CM code 203.02 has been added.

ICD-9-CM code 209.21 has been added to the “Secondary” ICD-9-CM code table for “Osteolytic bone metastasis of breast cancer.”

In the “Secondary” ICD-9-CM code table for “Moderate or severe hypercalcemia associated with malignancy, including Tamoxifen induced tumor flare”, the description for ICD-9-CM codes 203.00, 203.10, 203.80, 204.00, 204.10, 204.20, 204.80, 204.90, 205.00, 205.10, 205.20, 205.30, 205.80, 205.90, 206.00, 206.10, 206.20, 206.80, 206.90, 207.00, 207.10, 207.20, 207.80, 208.00, 208.10, 208.20, 208.80 and 208.90 has modified. ICD-9-CM codes 203.02, 203.12, 203.82, 204.02, 204.12, 204.22, 204.82, 204.92, 205.02, 205.12, 205.22, 205.32, 205.82, 205.92, 206.02, 206.12, 206.22, 206.82, 206.92, 207.02, 207.12, 207.22, 207.82, 208.02, 208.12, 208.22, 208.82, 208.92, 209.00-209.03, 209.10-209.17, 209.20-209.27 and 209.29 have been added. The ICD-9-CM code range listed in the "Coding Guidelines" section of the article has been expanded to include the 209 series in the first paragraph. ICD-9-CM code 209.21 has been added to the list of ICD-9-CM codes in the second paragraph of the “Coding Guidelines” section. The ICD-9-CM code range listed in the paragraph for "Moderate or severe hypercalcemia associated with malignancy, including Tamoxifen induced tumor flare" in the ICD-9-CM code section of the article has been expanded to include the 209 series.

Rituximab (Rituxan®) – Related to LCD L25820
A46093 (Article published October 2008): Source of revision – Internal (annual ICD-9-CM code updates for 2009). The “ICD-9-CM Codes That Support Medical Necessity” section of the article is modified as follows: the description for ICD-9-CM code 204.10 has been modified. ICD-9-CM code 204.12 has been added. Based on an external comment pemphigus vulgaris has been added as a covered indication and ICD-9-CM code 694.4 has been added to the “ICD-9-CM Codes That Support Medical Necessity” section of the article effective for dates of service on or after 07/18/2008. The first sentence in “Indications” has been revised to remove “FDA.”

Temsirolimus (Torisel ™) – Related to LCD L25820
A46089 (Article published October 2008): Source of revision – External: Based on an external comment a prognostic risk factor of hemoglobin less than the lower limit of normal has been added to the “Documentation Requirements” section of the article. The spelling of the drug has been corrected in the “Indications” section of the article. The first paragraph in the “Coding Guidelines” section has been revised to add that the site of metastasis should be coded as the secondary diagnosis effective for dates of service on or after 10/01/2008. ICD-9-CM codes have been added to the “ICD-9-CM Codes That Support Medical Necessity” section of the article.

Topotecan Hydrochloride (Hycamtin®) – Related to LCD L25820
A47580 (Article published October 2008): Source of revision – Internal (annual ICD-9-CM code updates for 2009). The “ICD-9-CM Codes That Support Medical Necessity” section of the article is modified as follows: the description for ICD-9-CM code 205.10 has been modified. ICD-9-CM code 205.12 has been added. The first sentence in “Indications” has been revised to remove “FDA.” Reference to “Hycamtin” has been removed from the “Indications” section of the article and approved indications have been combined.

Zoledronic Acid (e.g., Zometa ®, Reclast® ) – Related to LCD L25820
A46096 (Article published October 2008): Source of revision – Internal (annual ICD-9-CM code updates for 2009). The “ICD-9-CM Codes That Support Medical Necessity” section of the article is modified as follows:

In the first ICD-9-CM table for Zometa® (J3487) the description for ICD-9-CM code 203.00 has been modified. ICD-9-CM code 203.02 has been added.

The description for ICD-9-CM codes 203.00, 203.10, 203.80, 204.00, 204.10, 204.20, 204.80, 204.90, 205.00, 205.10, 205.20, 205.30, 205.80, 205.90, 206.00, 206.10, 206.20, 206.80, 206.90, 207.00, 207.10, 207.20, 207.80, 208.00, 208.10, 208.20, 208.80 and 208.90 has modified and ICD-9-CM codes 203.02, 203.12, 203.82, 204.02, 204.12, 204.22, 204.82, 204.92, 205.02, 205.12, 205.22, 205.32, 205.82, 205.92, 206.02, 206.12, 206.22, 206.82, 206.92, 207.02, 207.12, 207.22, 207.82, 208.02, 208.12, 208.22, 208.82, 208.92, 209.00-209.03, 209.10-209.17, 209.20-209.27 and 209.29 have been added to the “Secondary” ICD-9-CM code table for “Management of hypercalcemia of malignancy” for Zometa® (J3487). The “Indications” section of the article has been revised to remove “FDA” from the indications for Zometa® and Reclast®.